VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

ABSTRACT:

Purpose

A previously published study demonstrated a pharmacogenetic association between the minor alleles of 2 VEGFR2 single nucleotide polymorphisms (SNPs) and greater improvement in visual acuity (VA) to treatment with ranibizumab, an anti-vascular endothelial growth factor (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD). We evaluated whether this association was replicated among patients who participated in the Comparison of AMD Treatments Trials (CATT) or the Alternative Treatments to Inhibit VEGF in Patients with Age-Related Choroidal Neovascularisation (IVAN) trial.

Design

Cohort studies within randomized clinical trials.

Participants

Eight hundred thirty-five patients participating in CATT and 512 patients participating in IVAN.

SUBMITTER: Hagstrom SA 

PROVIDER: S-EPMC4516643 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature